Access the full text.
Sign up today, get DeepDyve free for 14 days.
W. Sweeley (1949)
Pathogenesis of atopic eczema.The Journal of the Medical Society of New Jersey, 46 8
Ruzicka (1989)
Leukotrienes in atopic eczemaActa Dermatol Venereol (Suppl. ) (Stockh), 144
J. Bernstein, P. Greenberger, R. Patterson, M. Glass, R. Krell, P. Thyrum (1991)
The effect of the oral leukotriene antagonist, ICI 204,219, on leukotriene D4 and histamine-induced cutaneous vascular reactions in man.The Journal of allergy and clinical immunology, 87 1 Pt 1
M. Krawiec, S. Wenzel (1999)
Use of leukotriene antagonists in childhood asthma.Current opinion in pediatrics, 11 6
T. Shimizu, S. Kristjánsson, G. Wennergren, I. Strannegård, B. Strandvik, Toshiaki Shimizu (1994)
Leukotriene B4 and C4 generation by blood leukocytes after ex vivo stimulation by Ca‐ionophore and opsonized zymosan in children with atopic dermatitisPediatric Allergy and Immunology, 5
Jan Bos, E. Wierenga, J. Smitt, F. Heijden, M. Kapsenberg (1992)
Immune dysregulation in atopic eczema.Archives of dermatology, 128 11
Markam (1998)
MonteleukastDrugs, 56
B. Knorr, J. Matz, J. Bernstein, Ha Nguyen, B. Seidenberg, T. Reiss, A. Becker (1998)
Montelukast for Chronic Asthma in 6- to 14-Year-Old Children A Randomized, Double-blind TrialJAMA, 279
(1998)
Lipid mediators of hypersensitivity and in ̄ammation
B. Volovitz, E. Tabachnik, M. Nussinovitch, B. Shtaif, H. Blau, I. Gil-ad, Abraham Weizman, I. Varsano (1999)
Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma.The Journal of allergy and clinical immunology, 104 6
K. Neuber, R. Hilger, W. König (1991)
Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis.Immunology, 73 1
M. Ellis (1998)
Successful treatment of chronic urticaria with leukotriene antagonists.The Journal of allergy and clinical immunology, 102 5
S. Weisberg (2000)
Pharmacotherapy of asthma in children, with special reference to leukotriene receptor antagonistsPediatric Pulmonology, 29
T. Ruzicka (1989)
Leukotrienes in atopic eczema.Acta dermato-venereologica. Supplementum, 144
R. Emerson, C. Charman, H. Williams (2000)
The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland gradingBritish Journal of Dermatology, 142
P. O'Byrne (1998)
Asthma treatment: antileukotriene drugs.Canadian respiratory journal, 5 Suppl A
Drazen (2000)
Treatment of asthma with drugs modifying the leukotriene pathwayN Engl J Med, 340
M. Lewis‐Jones, A. Finlay (1995)
The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical useBritish Journal of Dermatology, 132
A. Sala, S. Zarini, M. Bolla (1998)
Leukotrienes: lipid bioeffectors of inflammatory reactions.Biochemistry. Biokhimiia, 63 1
J. Drazen (1999)
Asthma therapy with agents preventing leukotriene synthesis or action.Proceedings of the Association of American Physicians, 111 6
B. Czarnetzki (1983)
Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses.Clinical and experimental immunology, 54 2
S. Spector, R. Tan (1998)
Antileukotrienes in chronic urticaria.The Journal of allergy and clinical immunology, 101 4 Pt 1
D. Maurer, G. Stingl (1995)
Immunoglobulin E-binding structures on antigen-presenting cells present in skin and blood.The Journal of investigative dermatology, 104 5
J. Drazen, E. Israel, P. OʼBYRNE (1999)
Treatment of asthma with drugs modifying the leukotriene pathway.The New England journal of medicine, 340 3
T. Rosenbach, J. Grabbe, A. Möller, H. Schwanitz, B. Czarnetzki (1985)
Generation of leukotrienes from normal epidermis and their demonstration in cutaneous diseaseBritish Journal of Dermatology, 113
AP Sampson, RU Thomas, JF Costello, Priscilla Piper (1992)
Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects.British journal of clinical pharmacology, 33 4
K. Fogh, Troels Herlin, K. Kragballe (1989)
Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations.The Journal of allergy and clinical immunology, 83 2 Pt 1
Cox, Moffatt, Faux, Walley, Coleman, Trembath, Cookson, Harper (1998)
Association of atopic dermatitis to the beta subunit of the high affinity immunoglobulin E receptorBritish Journal of Dermatology, 138
T. Ruzicka, J. Ring (1987)
Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema.Acta dermato-venereologica, 67 6
J. Hanifin, G. Rajka (1980)
Diagnostic Features of Atopic DermatitisActa Dermato-Venereologica
The primary action of leukotrienes includes contraction of human airway muscle, chemotaxis, and increased vascular permeability, with secondary effects of inhibiting allergen‐induced early and late responses. Although there is limited available information and research regarding leukotrienes in atopic dermatitis (AD), there is evidence to support their role in the pathogenesis of the disease. We conducted a pilot study to test the efficacy of montelukast, a cysteinyl‐leukotriene‐1 receptor antagonist, in 15 patients (6–16 years of age) with moderate‐to‐severe AD, using a randomized double‐blind placebo‐controlled crossover study. These patients had chronic moderate‐to‐severe AD, despite being on conventional therapy. They were randomized either to placebo for 4 weeks and then the study drug for 4 weeks, or vice versa. There was a 2‐week run‐in period for all participants before commencement of the study, and a 2‐week washout before crossover. At enrollment and on each follow‐up visit, every patient was assessed by a single observer and objectively scored for disease extent and severity. A subjective score was given for the impact of eczema on daily living. There was statistical improvement in patents on active treatment compared with placebo in the severity of AD (p < 0.05). Our findings suggest that leukotriene receptor antagonist as an adjunct treatment has an anti‐inflammatory effect on moderate‐to‐severe AD. A larger trial is needed to ascertain its efficacy fully.
Pediatric Allergy and Immunology – Wiley
Published: Jun 1, 2001
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.